RxDoctor Payments Data

Shana Standard, PA

Physician Assistant · Savannah, GANPI 1417977562

Payments from drug & device makers

$8,408in general payments, 2019–2025

Across 500 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$843
  • AbbVie$822
  • Lilly USA, LLC$744
  • AstraZeneca$627
  • Boehringer Ingelheim$609
  • Novartis$451
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,408 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$32,451
Medicare patients
216
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$126,164
EliquisApixaban118$98,740
JardianceEmpagliflozin68$77,407
MounjaroTirzepatide54$68,110
RybelsusSemaglutide24$47,458
Tresiba Flextouch U-200Insulin Degludec35$41,962
FarxigaDapagliflozin Propanediol32$35,459
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,571
EntrestoSacubitril/Valsartan19$22,212
LinzessLinaclotide30$20,350
XareltoRivaroxaban21$18,664
TrulicityDulaglutide18$18,516
UbrelvyUbrogepant11$15,559
GemtesaVibegron13$13,994
Repatha SureclickEvolocumab11$12,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$843$173,62196 claims
PfizerEliquis, Paxlovid$424$100,107144 claims
Lilly USA, LLCMounjaro, Trulicity$744$86,62772 claims
Boehringer IngelheimJardiance, Combivent Respimat$609$85,84185 claims
AbbVieLinzess, Ubrelvy, Synthroid$822$37,38767 claims
AstraZenecaFarxiga$627$35,45932 claims
GSKTrelegy Ellipta, Breo Ellipta$253$31,06742 claims
NovartisEntresto$451$22,21219 claims
Johnson & JohnsonXarelto$58$18,66421 claims
Sumitomo Pharma America, Inc.Gemtesa$27$13,99413 claims
MerckJanuvia$408$12,33620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →